Philip Spanheimer Profile
Philip Spanheimer

@PSpanheimer

Followers
554
Following
1K
Media
27
Statuses
256

Surgeon-Scientist @UNC | Training: Iowa Surgery, MSKCC | Clinic: Breast Cancer, Sarcoma | NCI-funded Lab: molecular genetics, targeted therapeutics.

Joined October 2018
Don't wanna be here? Send us removal request.
@jigdeneve
Jeremiah Deneve
2 months
Superb UNC-Duke Surg Onc journal club on Gastric/GEJ cancers. Excellent discussion and presentations by @SocSurgOnc 1st & 2nd yr CGSO Fellows! So much to learn from these talented superstars! @DukeSurgOnc @UNCSurgery @YehlabUNC @PSpanheimer @globalsurgallie @michael_lidsky
1
6
15
@kibbemr
Melina Kibbe
7 months
Outstanding presidential address Dr. Ron Weigal at the American Surgical Association annual meeting!
0
8
45
@DamaniaLab
Blossom Damania 🔬🧬🧪🦠🧫
9 months
NIH funding creates medicines, jobs, and economic growth
27
169
392
@PSpanheimer
Philip Spanheimer
1 year
I study breast cancer in large part because of my time @UIowa_Surgery in the Weigel lab. Well deserved honor for a truly exceptional mentor.
@TomVargheseJr
Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸
1 year
One of the perks of being Society of University Surgeons @UnivSurg President is the honor of announcing the SUS Lifetime Achievement Award winner, the highest honor in our organization. Please join me in congratulating the 2024 SUS LTAA winner - Dr. Ron Weigel @UIowa_Surgery .
2
1
16
@BCRFcure
The Breast Cancer Research Foundation
1 year
While it’s very rare, male breast cancer can be more challenging to treat and has poorer outcomes compared to breast cancer in women. As we close out #MensHealthMonth, we highlight BCRF investigator Dr. Jose Pablo Leone, who seeks to address this. https://t.co/tQlcYEBf1g
Tweet card summary image
bcrf.org
Dr. Jose Pablo Leone discusses breakthroughs in treating male breast cancer. Learn about clinical trials and new therapies. Support innovative research now!
1
10
21
@Yoshiko_Iwai
Yoshiko Iwai, MD, MS, MFA
1 year
Tremendously grateful to @PSpanheimer @Dr_X_25 @kimhjUNC and our collaborators at @UNC_Lineberger @UNCSurgery for making this possible. Thank you for letting me join the team!
0
1
4
@PSpanheimer
Philip Spanheimer
1 year
Had a lot of fun operating with @Dr_X_25 on his last day @UNCSurgery. @MSKCancerCenter - he’s ready for you. @MichaelDAngeli2 @KevinCSoaresMD @JoshSmithMDPhD @SDownsCanner
1
5
54
@jigdeneve
Jeremiah Deneve
1 year
We are thrilled to announce that @KellyHerremans has matched @UNCSurgery as our 2025 incoming #CGSO Fellow! Proud of you and looking forward to a bright future! @UFSurgery @JoseTrevinoMD @CapriceGreenber @SocSurgOnc @PSpanheimer @YehlabUNC @kimhjUNC @RunLiz @UNC_Lineberger
0
7
30
@SDownsCanner
Stephanie Downs-Canner
2 years
Look out for UNC resident Selena An! She gave a beautiful oral presentation at #SSO2024 @PSpanheimer @UNCSurgery @SocSurgOnc
0
2
24
@PSpanheimer
Philip Spanheimer
2 years
So proud of @UNCSurgery resident @SelenaAnMD on her excellent presentation #sso2024. @Dr_KGallagher
2
3
44
@SDownsCanner
Stephanie Downs-Canner
2 years
Please join us @SocSurgOnc #SSO2024 in Atlanta on Thursday at noon to learn more about our amazing fellowship in Breast Surgical Oncology! @MSKCancerCenter @ASBrS. You might even meet some of our current amazing fellows! @GinaMatar @krpawloski @juliamchandler
0
9
34
@UNCSurgery
UNC Surgery
2 years
Why do some patients with #breastcancer respond to treatment and some do not? Philip Spanheimer, MD and collaborators advance depth of exploration in how breast tumors become resistant to therapy: https://t.co/0pnUXa3RaG @PSpanheimer | @UNC_Lineberger | @UNC_SOM
0
6
22
@PSpanheimer
Philip Spanheimer
2 years
Fantastic grand rounds yesterday by @Dr_X_25 on immunotherapy in cancer from work in @SDownsCanner lab. Soon-to-be @MSKCancerCenter fellow. It’s been fun watching your progress so far! @UNCSurgery @CapriceGreenber @kimhjUNC @jigdeneve @Dr_KGallagher @RunLiz @LarryTKim @dgerber6
1
4
30
@ac_palmer
Adam C Palmer
2 years
New paper: Most approved drug combinations for advanced cancer (1995-2020) have predictable clinical efficacy, because they have additive effect on Progression-Free Survival times. In @NatureCancer at https://t.co/Z7xabVpouT by @HaeunHwangbo @SC_Patterson @PlanaDeborah 1/6
10
143
469
@PSpanheimer
Philip Spanheimer
2 years
Great work @kchen315 !
@kchen315
Kevin Chen
2 years
We developed an AI model which can use intra-op specimen mammography to predict the pathologic margin status of partial mastectomy specimens with accuracy equal to surgeons and radiologists. @Dr_KGallagher @shawnmgomez https://t.co/rY02054J7r
0
0
5
@PSpanheimer
Philip Spanheimer
2 years
Tweet card summary image
pubmed.ncbi.nlm.nih.gov
This novel ex vivo model system now provides the foundation to define responsive and resistant subpopulations within heterogeneous human tumors, which can be used to develop precise single cell-based...
@PSpanheimer
Philip Spanheimer
3 years
NEW PREPRINT: https://t.co/w1YXIUaodE Intratumor heterogeneity is associated with worse outcomes and poor response to treatment across human solid organ tumors - so can we measure distinct responses in distinct cell types? Is that informative?
2
5
22
@PSpanheimer
Philip Spanheimer
2 years
So proud of @graypeery9. Asked a question in clinic, designed a study and saw it through to publication. Does your scribe do that????? @UNC_SOM 👀 out for her application!! @Dr_KGallagher @UNC_Lineberger @UNCSurgery @lauraburkbauer https://t.co/ChdTqtQGIc
0
5
25
@PgambarRaj
Paigambar Raj
2 years
Our review on advances in the management of Early-Stage Triple-Negative Breast Cancer #bcsm @UNC_Lineberger @prarthnavb @PSpanheimer @brunklab
@prarthnavb
Prarthna Bhardwaj
2 years
Happy to share our review article on advances in early stage triple negative breast cancer @IJMS_MDPI. A wonderful collaboration with my @ASCO mentor extraordinaire @YAbdouMD and colleagues. #bcsm #tnbc https://t.co/In4SmCZxXe
0
10
19